EC Number   |
Application |
Reference |
|---|
   3.4.17.20 | diagnostics |
the activation peptide of procarboxypeptidase B, set free during activation of procarboxypeptidase B, is a marker for acute pancreatitis |
670466 |
| 3.4.17.20 | medicine |
a range of fibrinolytic kinetic values and the contribution of thrombin activatable fibrinolysis inhibitor in normal subjects are established. Study of disease states involving potential hypofibrinolysis can be conducted using this system to link fibrinolytic vulnerability and thrombophilia |
696925 |
| 3.4.17.20 | medicine |
agents that improve the efficiency of TAFI to downregulate fibrinolysis might become available for the treatment of bleeding disorders such as hemophilias A and B |
653977 |
| 3.4.17.20 | medicine |
argatroban enhances fibrinolysis via a differential inhibition of thrombin-mediated activation of TAFI and factor XIII |
696929 |
| 3.4.17.20 | medicine |
coagulation pathway in patients with non-small-cell lung cancer (NSCLC) is investigated: The TAFI activity, prothrombin fragment 1 + 2 levels, and tissue factor pathway inhibitor activity are significantly higher in patients with lung cancer than in subjects in the control group. There is no statistically significant associations between TAFI activity levels and patient age, sex, body mass index, histopathology, or stage of disease |
697425 |
| 3.4.17.20 | medicine |
important differences in the hemostatic parameters between the patients with hypothyroidism and healthy controls are found. Increased FVII, TM, and TAFI and decreased FV, FVIII, vWF, protein C, protein S, and TFPI in these patients represent a potential hypercoagulable and hypofibrinolytic state, possible endothelial dysfunction, which might augment the risk for atherosclerotic and atherothrombotic complications in patients with hypothyroidism |
697622 |
| 3.4.17.20 | medicine |
in Hashimoto thyroiditis, patients have high levels of TAFI activity compared to controls. A high level of TAFI activity suggests fibrinolytic deficit or thrombotic tendency in hypothyroid patients and this deficit is persistent after L-thyroxine replacement |
698377 |
| 3.4.17.20 | medicine |
it is investigated whether it is possible to detect the activation of the proCPU/CPU system during therapeutic thrombolysis of patients with acute ischemic stroke: activation of the proCPU system during intravenous recombinant tissue plasminogen activator and intra-arterial administration of urokinase in patients with acute ischemic stroke is shown |
699864 |
| 3.4.17.20 | medicine |
no significant difference in lipid parameters is determined between patients with polycystic ovary syndrome and healthy controls. In addition, no difference in CIMT measurements and TAFI levels between patients with polycystic ovary syndrome and healthy controls is shown |
697791 |
| 3.4.17.20 | medicine |
pregnancy is associated with elevated plasma TAFI antigen levels but no additional effect of gestational diabetes is found on plasma TAFI antigen levels beyond pregnancy |
697552 |
